Iovance Biotherapeutics Reports Q4 2025 Earnings; Revenue Down 15% YoY

Iovance Biotherapeutics reported Q4 and full-year 2022 financial results. Revenue for the quarter was $79.8 million, up 44% YoY, driven by higher product sales and collaboration revenue. The company also reported a net loss of $93.7 million, compared to a net loss of $55.9 million in Q4 2021. For the full year 2022, revenue was $292.1 million, up 60% YoY, and the net loss was $351.4 million.